机构评级详情见下表： 海吉亚医疗港股市值71.75亿港元，在医疗服务Ⅱ行业中排名第7。主要指标见下表： 海吉亚医疗(06078.HK)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股东周年大会授 出的购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易所有限公司购 回最多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 截至2025年12月15日收盘，海吉亚医疗(06078.HK)报收于11.63港元，上涨0.26%，成交量458.22万股， 成交额5312.35万港元。投行对该股的评级以买入为主，近90天内共有1家投行给出买入评级。中信建投 最新一份研报给予海吉亚医疗买入评级。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Goldman Sachs maintains a "Neutral" rating on Alibaba Health (00241.HK) following the release of its mid-term results for the fiscal year ending September 2026, citing structural benefits from the outflow of original prescription drugs from hospital channels and accelerated online drug penetration [1] Financial Performance - Alibaba Health's revenue forecast for fiscal years 2026 to 2028 has been slightly adjusted to a growth of 2% to 4%, with corresponding adjustments to the adjusted net profit forecast also increased by 2% to 4% [1] - The target price has been raised from HKD 4.7 to HKD 5.2 based on a projected 28 times price-to-earnings ratio for its pharmacy and medical services business in 2027 [1] Market Position - As of December 2, 2025, Alibaba Health's stock closed at HKD 5.45, down 1.09%, with a trading volume of 77.95 million shares and a turnover of HKD 425 million [1] - The market capitalization of Alibaba Health is HKD 89.123 billion, ranking second in the medical services sector [2] Institutional Ratings - Recent ratings from various investment banks include: - Huatai Securities: Buy rating with a target price of HKD 6.08 [1] - Guosen Securities: Outperform rating [1] - CICC: Outperform rating with a target price of HKD 7.10 [1] - CITIC Securities: Awaiting rating with a target price of HKD 9.60 [1] Key Financial Metrics - Return on Equity (ROE): 8.22%, significantly higher than the industry average of 0.02% [2] - Revenue: HKD 28.344 billion, ranking third in the industry [2] - Net Profit Margin: 5.39%, compared to an industry average of -843.36% [2] - Debt Ratio: 24.76%, much lower than the industry average of 74.15% [2]

| 股票代码｜股票简称｜ 投行名称 ｜ 发布日期｜ 评级 ｜目标价（港元） | | | --- | --- | | 02666.HK 环球医疗 太平洋证券 2025-10-31 买人 | 7.97 | | 02666.HK 环球医疗 国信证券 2025-09-30 优于大市 | | | 02666.HK 环球医疗 华安证券 2025-09-25 增持 | | 环球医疗(02666.HK)发布公告，公司的全资附属公司中国环球租赁有限公司已得到中国证券监督管理委 员会批复核准，在中华人民共和国面向合格投资者公开发行本金总额最高达人民币80亿元的境内公募公 司债。截至本公告日期，该公司债之剩余额度为人民币54亿元。该公司债采用分期方式发行，发行人 2025年第四期公司债的发行本金总额不超过人民币10亿元(含人民币10亿元)，基础期限五年，附第3年 末及第4年末发行人赎回选择权、调整票面利率选择权及投资者回售选择权。 截至2025年12月1日收盘，环球医疗(02666.HK)报收于6.28港元，上涨0.32%，成交量229.3万股，成交额 1431.4万港元。投行对该股的评级以增持为主，近90天内共有1家投行给出增持 ...

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 160,000 shares at a total cost of HKD 277,200, with a buyback price ranging from HKD 1.72 to HKD 1.74 per share [1] Company Summary - As of November 26, 2025, Hema Medical's stock closed at HKD 1.74, reflecting a 0.58% increase with a trading volume of 320,000 shares and a turnover of HKD 553,000 [1] - The market capitalization of Hema Medical is HKD 2.142 billion, ranking 15th in the medical services sector [1] Financial Metrics - Return on Equity (ROE): -6.36%, compared to the industry average of -0.02%, ranking 39th in the sector [1] - Market Capitalization: HKD 2.142 billion, while the industry average is HKD 7.938 billion, ranking 15th [1] - Revenue: HKD 1.935 billion, with the industry average at HKD 3.832 billion, ranking 15th [1] - Net Profit Margin: 5.95%, significantly better than the industry average of -843.36%, ranking 25th [1] - Gross Profit Margin: 31.12%, compared to the industry average of 39.76%, ranking 28th [1] - Debt Ratio: 29.8%, much lower than the industry average of 74.15%, ranking 21st [1]

Core Points - The company, Hema Medical (03309.HK), announced a share buyback of 200,000 shares for a total cost of HKD 342,400 on November 24, 2025 [1] - As of the market close on November 24, 2025, Hema Medical's stock price was HKD 1.71, reflecting a decline of 1.16% with a trading volume of 682,000 shares and a turnover of HKD 1.168 million [1] - The stock has not received any ratings from investment banks in the past 90 days, indicating low analyst coverage [1] Company Performance Metrics - Hema Medical's market capitalization is HKD 2.143 billion, ranking 15th in the medical services sector [1] - Key performance indicators compared to the industry average: - Return on Equity (ROE): -6.36% vs. 0.02% (ranked 39th) [1] - Market capitalization: HKD 2.143 billion vs. HKD 7.725 billion (ranked 15th) [1] - Revenue: HKD 1.935 billion vs. HKD 3.832 billion (ranked 15th) [1] - Net Profit Margin: 5.95% vs. -843.36% (ranked 25th) [1] - Gross Profit Margin: 31.12% vs. 39.76% (ranked 28th) [1] - Debt Ratio: 29.8% vs. 74.15% (ranked 21st) [1]

Group 1 - The core point of the article is that Global Medical (02666.HK) has seen a significant shareholder transfer of stock valued at HKD 1.236 billion, representing 9.37% of its shares, from GF Securities Hong Kong to Cinda International Securities [1] - Investment banks predominantly rate Global Medical as "Buy," with one bank issuing a "Buy" rating in the last 90 days and a target price of HKD 7.97 [1] - Pacific Securities has recently issued a report giving Global Medical a "Buy" rating with a target price of HKD 7.97 [1] Group 2 - Global Medical has a market capitalization of HKD 13.193 billion, ranking 5th in the healthcare services sector [1] - Key financial metrics for Global Medical compared to the industry average are as follows: ROE at 12.39% (industry average 0.02%), revenue at HKD 14.701 billion (industry average HKD 3.832 billion), net profit margin at 17.61% (industry average -843.36%), gross margin at 34.34% (industry average 39.76%), and debt ratio at 73.38% (industry average 74.15%) [1]

Core Viewpoint - JD Health (06618.HK) is expected to see strong revenue and profit growth in Q3 2025, driven by the expansion of insurance payment coverage, offline service development, and deepening AI medical applications, solidifying its leading position in the pharmaceutical e-commerce sector. The company has a positive growth outlook, with a "Buy" rating from multiple investment banks [1]. Group 1: Company Performance - JD Health's market capitalization is HKD 220.101 billion, ranking first in the healthcare services sector [1]. - The company reported a revenue of HKD 65.106 billion, significantly higher than the industry average of HKD 3.832 billion, also ranking first in this metric [2]. - JD Health's net profit margin stands at 7.34%, while the industry average is at -843.36%, placing it 23rd in the industry ranking [2]. Group 2: Investment Ratings - In the past 90 days, seven investment banks have issued "Buy" ratings for JD Health, with a target average price of HKD 75.53 [1]. - The latest ratings from various investment banks include: - Guohai Securities: Buy [1] - Caitong Securities: Buy [1] - Zhonghui Company: Outperform with a target price of HKD 71.40 [1] - Xinda Securities: Buy [1] - Huatai Securities: Buy with a target price of HKD 68.30 [1] - Zhongquan Company: Outperform with a target price of HKD 67.40 [1] - CITIC Securities: Buy with a target price of HKD 95.00 [1]

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 60,000 shares at a price range of HKD 1.80 to HKD 1.81, totaling HKD 10.85 million, on November 17, 2025 [1] Company Summary - As of November 17, 2025, Hema Medical's stock closed at HKD 1.80, down 1.64%, with a trading volume of 207,800 shares and a turnover of HKD 374,300 [1] - The company has a market capitalization of HKD 2.268 billion and ranks 16th in the medical services sector [1] Financial Metrics - Return on Equity (ROE): -6.36%, compared to the industry average of 0.02%, ranking 39th out of 60 [1] - Market Capitalization: HKD 2.268 billion, while the industry average is HKD 8.332 billion, ranking 16th out of 60 [1] - Revenue: HKD 1.935 billion, with the industry average at HKD 3.832 billion, ranking 15th out of 60 [1] - Net Profit Margin: 5.95%, compared to an industry average of -843.36%, ranking 25th out of 60 [1] - Gross Profit Margin: 31.12%, while the industry average is 39.76%, ranking 28th out of 60 [1] - Debt Ratio: 29.8%, compared to the industry average of 74.15%, ranking 21st out of 60 [1]

Group 1 - The company, Universal Medical (02666.HK), announced the issuance of its first phase of notes by its wholly-owned subsidiary, Universal Global International Financing Leasing (Tianjin) Co., Ltd., with a total issuance amount of RMB 200 million at a fixed interest rate of 2.08% [1] - The notes will mature in two years from November 11, 2025, and were issued at a price equivalent to 100% of their face value [1] - As of November 11, 2025, Universal Medical's stock closed at HKD 6.55, with a trading volume of 4.364 million shares and a turnover of HKD 28.423 million [1] Group 2 - The company has a market capitalization of HKD 12.352 billion, ranking 5th in the medical services sector [2] - Key financial metrics include a Return on Equity (ROE) of 12.39%, revenue of HKD 14.701 billion, and a net profit margin of 17.61% [2] - The company's gross profit margin stands at 34.34%, while its debt ratio is 73.38%, which is slightly lower than the industry average [2]

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of approximately HKD 537,100 for 300,000 shares at a price range of HKD 1.77-1.81 per share, indicating a strategic move to enhance shareholder value [1] Company Summary - As of November 4, 2025, Hema Medical's stock closed at HKD 1.81, down 0.55%, with a trading volume of 936,000 shares and a turnover of HKD 1.6597 million [1] - The company has a market capitalization of HKD 2.259 billion, ranking 15th in the medical services sector [1] Industry Summary - Hema Medical's key financial metrics compared to the industry average are as follows: - Return on Equity (ROE): -6.36% vs. industry average of -0.02%, ranking 39th [1] - Market capitalization: HKD 2.259 billion vs. industry average of HKD 7.906 billion, ranking 15th [1] - Revenue: HKD 1.935 billion vs. industry average of HKD 3.832 billion, ranking 15th [1] - Net Profit Margin: 5.95% vs. industry average of -843.36%, ranking 25th [1] - Gross Profit Margin: 31.12% vs. industry average of 39.76%, ranking 28th [1] - Debt Ratio: 29.8% vs. industry average of 74.15%, ranking 21st [1] - There has been low attention from investment banks, with no ratings given in the past 90 days [1]